- Home
- SPRO vs GLQ Comparison
SPRO vs GLQ Comparison
Compare SPRO & GLQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- GLQ
- Stock Information
- Founded
- SPRO 2013
- GLQ 2005
- Country
- SPRO United States
- GLQ United States
- Employees
- SPRO N/A
- GLQ N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- GLQ Finance/Investors Services
- Sector
- SPRO Health Care
- GLQ Finance
- Exchange
- SPRO Nasdaq
- GLQ Nasdaq
- Market Cap
- SPRO 136.7M
- GLQ 144.8M
- IPO Year
- SPRO 2017
- GLQ N/A
- Fundamental
- Price
- SPRO $2.24
- GLQ $7.47
- Analyst Decision
- SPRO Buy
- GLQ
- Analyst Count
- SPRO 2
- GLQ 0
- Target Price
- SPRO $5.00
- GLQ N/A
- AVG Volume (30 Days)
- SPRO 504.7K
- GLQ 65.5K
- Earning Date
- SPRO 11-13-2025
- GLQ 01-01-0001
- Dividend Yield
- SPRO N/A
- GLQ 11.11%
- EPS Growth
- SPRO N/A
- GLQ N/A
- EPS
- SPRO N/A
- GLQ N/A
- Revenue
- SPRO $40,549,000.00
- GLQ N/A
- Revenue This Year
- SPRO N/A
- GLQ N/A
- Revenue Next Year
- SPRO N/A
- GLQ N/A
- P/E Ratio
- SPRO N/A
- GLQ N/A
- Revenue Growth
- SPRO N/A
- GLQ N/A
- 52 Week Low
- SPRO $0.51
- GLQ $5.13
- 52 Week High
- SPRO $3.22
- GLQ $6.54
- Technical
- Relative Strength Index (RSI)
- SPRO 43.25
- GLQ 37.48
- Support Level
- SPRO $2.33
- GLQ $7.38
- Resistance Level
- SPRO $2.57
- GLQ $7.99
- Average True Range (ATR)
- SPRO 0.15
- GLQ 0.13
- MACD
- SPRO -0.03
- GLQ -0.04
- Stochastic Oscillator
- SPRO 0.00
- GLQ 14.75
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About GLQ Clough Global Equity Fund Clough Global Equity Fund of Beneficial Interest
Clough Global Equity Fund is a closed-end management investment company. Its investment objective is to provide a high level of total return. The Fund invests in the equity, equity-related securities, and fixed-income securities in both U.S. and non-U.S. markets.